Inventiva FY2026 EPS Estimate Increased by HC Wainwright

Inventiva S.A. (NASDAQ:IVA) – Analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of Inventiva in a note issued to investors on Tuesday, October 15th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($2.43) for the year, up from their previous forecast of ($3.22). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Inventiva’s current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Inventiva’s FY2027 earnings at ($3.06) EPS and FY2028 earnings at $1.20 EPS.

Separately, Stifel Nicolaus cut their price target on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, September 26th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Inventiva has a consensus rating of “Buy” and a consensus price target of $16.25.

Inventiva Stock Performance

Shares of IVA opened at $2.63 on Friday. Inventiva has a 12 month low of $1.53 and a 12 month high of $4.75. The firm has a fifty day simple moving average of $2.17 and a 200 day simple moving average of $2.78.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new position in shares of Inventiva S.A. (NASDAQ:IVA) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.